Table 1.
Adverse effects and frequencies of new targeted therapies.
| Treatment | Adverse Effects | |||||
|---|---|---|---|---|---|---|
| Infection (Grade ≥ 3) | Neutropenia | Diarrhea | Hypertension | Hemorrhage/Bleeding | References | |
| Immune checkpoint inhibitor | 2–7% | - | 1–25% | - | - | [2,3,4] |
| BTK inhibitors | ||||||
| Ibrutinib | 11–48% | 4–17% | 5–68% | 5–22% | 3–15% | [5,6,7,8] |
| Zanubrutinib | 27% | 36% | 23% | 12% | 3% | [9] |
| Acalabrutinib | 18% | 12% | 37% | 8% | 4% | [10] |
| Orelabrutinib | 15% | 29% | 7% | - | 1% | [11] |
| Fenebrutinib | 17% | 4% | 29% | - | 1% | [12] |
| PI3K inhibitors | ||||||
| Idelalisib | 20–35% | 56% | 30–45% | - | - | [13,14,15] |
| Duvelisib | 51–68% | 26–50% | 43–52% | - | - | [16,17] |
| Umbralisib | - | 14–35% | 26–43% | - | - | [18,19] |
| Anti-apoptotic protein BCL-2 inhibitors | 70–75% | 40–50% | 41% | - | - | [20] |
| Janus Kinase inhibitors | 30–35% | - | - | - | - | [21] |
| CAR-T cell therapy | 10–31% | 53–87% | - | - | - | [22,23,24] |
BTK: Bruton’s Tyrosine Kinase, PI3K: Phosphatidylinositol 3-kinase, JAK: Janus Kinase.